

Original Article

ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer

Wei Fan^{1*}, Haikou Yang^{2*}, Hong Xue³, Yong Sun⁴, Jun Zhang¹

¹Department of Anesthesiology, Huai'an First People's Hospital, Nanjing Medical University, Jiangsu, China;

²Department of Anesthesiology, Maternal & Child Health Care Hospital of Huai'an, Jiangsu, China; ³Department of Anesthesiology, Huai'an Hospital Affiliated of Xuzhou Medical College and Huai'an Second People's Hospital, Jiangsu, China; ⁴Department of Burn and Plastic Surgery, Huai'an First People's Hospital, Nanjing Medical University, Jiangsu, China. *Equal contributors.

Received March 10, 2015; Accepted April 24, 2015; Epub May 1, 2015; Published May 15, 2015

Abstract: Background: To investigate the diagnostic and prognostic value of engulfment and cell motility (*ELMO3*) in non-small cell lung cancer (NSCLC). Methods: The expression of *ELMO3* at mRNA levels were detected using reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) in 125 NSCLC patients' tissues and adjacent tissues, as well as in the serum of 125 NSCLC patients and 89 healthy controls. Then, receiver operating characteristic curve (ROC), Kaplan-Meier and Cox regression analysis were adopted to estimate the potential diagnostic and prognostic value of *ELMO3*, respectively. Results: *ELMO3* expression level was significantly up-regulated in NSCLC patients' tissues and serum compared with controls ($P < 0.001$). Moreover, the expression of *ELMO3* was significantly associated with tumor size ($P = 0.020$), TNM stage ($P = 0.017$), lymph node metastasis ($P = 0.045$) and distance metastasis ($P = 0.033$). ROC showed the AUC was 0.917, and the optimal cutoff value was 0.735, providing a sensitivity of 92.8% and a specificity of 84.3%. Furthermore, Kaplan-Meier analysis indicated the high expression of *ELMO3* could lead to a shorter overall survival time. In multivariate analysis, *ELMO3* expression (HR=3.378, 95% CI=1.326-8.587, $P = 0.011$) was proved to be linked with the prognosis of NSCLC and might act as an independent prognostic marker. Conclusion: The over-expression of *ELMO3* was a potential diagnostic and prognostic marker for NSCLC.

Keywords: Non-small cell lung cancer, *ELMO3*, diagnosis, prognosis

Introduction

Lung cancer is a major cause of cancer-related death in worldwide, accounting for 18% (1.4 million) of cancer deaths in 2008 according to global cancer statistics [1]. It is traditionally classified into two major subtypes, small cell lung cancer and non-small cell lung cancer (NSCLC). Among them, NSCLC covers 80-85% [2]. Although the survival rate of patients with NSCLC has been improved due to the advances in surgical techniques and treatment strategies, the high rate of recurrence and metastasis were still lead to a short-term survival after surgical resection [3, 4]. NSCLC is a slow-developing cancer with a complex pathogenesis and its progression get involve in several stages as well as activation of many oncogenes and inactivation of tumor suppressor genes [5]. Because of the late-stage diagnosis and other complex

factors, NSCLC has a poor prognosis and low cure rate. Therefore, the research for effective molecular markers for diagnosis and prognosis of lung cancer is an important issue at present.

The engulfment and cell motility (*ELMO*) proteins family which consists of *ELMO1*, *ELMO2*, and *ELMO3*, widely distribute in mammals and participate in a various of life action including cell migration, cell chemotaxis transfer, cell polarity, apoptosis, dendritic development and so on [6-10]. Ras GTPase-binding domain (RBD) that only present in Elmo proteins and ElmoD protein (Elmo domain) is the most important characteristic of *ELMO* [11, 12]. In previous studies, most of the researches were about the function of *ELMO1* and *ELMO2*, the investigation about *ELMO3* was rarely. It was reported that *ELMO3* plays important roles in the cell




Figure 1. Expression level of *ELMO3* in NSCLC tissues and serum detected. A. The expression of *ELMO3* in NSCLC tissues was significantly higher than in adjacent tissues ($P<0.05$). B. The serum *ELMO3* expression were also markedly up-regulated in patients with NSCLC compared with healthy controls ($P<0.05$).

renewing and migration processes within the intestinal epithelia and in colorectal cancer [13]. Besides, *ELMO3* had been considered to be a promoter of metastatic dissemination of NSCLC in the study of Sjøes et al. [14]. However, the diagnostic and prognostic of *ELMO3* in NSCLC remains unknown.

In this study, we investigated the expression level of *ELMO3* in NSCLC tissues and serum through quantitative real-time polymerase chain reaction (qRT-PCR), and analyzed the association of *ELMO3* with clinicopathological

characteristics. Meanwhile, the diagnostic and prognostic values of *ELMO3* were also estimated.

Materials and methods

Patients and samples

A total of 125 patients with NSCLC were recruited. The study was permitted by the Ethics Committee of the hospital. None of them had received any adjuvant chemotherapy or radiotherapy. Besides, 89 healthy volunteers matching age and gender were obtained as healthy controls. Meanwhile, written informed consents had been signed by each participants in advance.

The tissues and adjacent tissues were collected from NSCLC patients and the serum was reserved. The serum from healthy controls were extracted, too. All the tissues were frozen by liquid nitrogen while the serum samples were put into blood collection tube of EDTA and stored at -80°C for RNA extraction. A 5-years' follow-up was performed to estimate the prognosis of NSCLC patients who had undergone curative surgical resection. The clinicopathologic characteristics including age, gender, tumor size, TNM stage, lymph node metastasis, and distant metastasis were recorded in a database. Patients who died from unexpected events or other diseases were excluded from our study.

RNA extraction and quantitative real-time polymerase chain reaction (QRT-PCR)

Total RNA was isolated from the tissues and adjacent tissues of 125 patients with NSCLC as well as the serum samples using the Trizol reagent (Invitrogen). The RNA was purified to the OD A260/A280 ratio reach to 2.0, the anal-

Table 1. Relationship between *ELMO3* expression and clinicopathological characteristics in NSCLC

Characteristic	Cases	<i>ELMO3</i> expression		χ^2	P-values
		Low N=55	High N=70		
Gender					
Male	72	30	42	0.982	0.322
Female	53	25	28		
Age (years)					
≤60	83	40	43	1.762	0.184
>60	42	15	27		
Tumor size					
≤5 cm	89	45	44	5.400	0.020
>5 cm	36	10	26		
TNM stage					
Stage I	102	50	52	5.299	0.017
Stage II/III	23	5	18		
Lymph node metastasis					
Yes	34	10	24	4.034	0.045
No	91	45	46		
Distant metastasis					
Absent	98	48	50	4.566	0.033
Present	27	7	20		

ysis would be subsequently conducted. Reverse transcription was performed to synthesize the first chain of cDNA according to the TaqMan microRNA assay protocol (Applied Biosystems, Foster City, CA, USA). Then the RT-PCR reaction was carried out in the Applied Biosystems 7900 Fast Real-Time PCR system (Applied Biosystems, Foster City, California, USA). *ELMO3* primers were: forward; 5'-GGC CTT CTC AGA GCT CAT G-3' and reverse; 5'-TGA GGT TCA TGT TCA CGT AGC-3'. β -actin was taken as an internal control. Each sample was examined in triplicate, and the relative quantification of *ELMO3* expression was evaluated by the comparative cycle threshold (CT) method, normalized to β -actin.

Statistical analysis

All statistical analyses were performed using SPSS version 18.0 software. The data was stated as mean \pm SD. The differences of *ELMO3* expression between NSCLC tissues and adjacent tissues as well between NSCLC serum and healthy serum were estimated via students' T-test, respectively. The correlations between *ELMO3* expression and clinicopathologic parameters were analyzed by chi-square test. The diagnostic value of serum *ELMO3* expres-

sion was evaluated through the establishment of receiver operating characteristic curve (ROC). Kaplan-Meier analysis was used to determine the overall survival time of patients with different expression of *ELMO3*. The log-rank test was used to analyze the significance of the result. Multivariate analyses were performed using Cox regression analysis to determine the factors affecting the prognosis of NSCLC. The difference was considered to be statistically significant when the *P* value was less than 0.05.

Results

Expression of ELMO3 was increased in NSCLC tissues and serum

To detect the expression of *ELMO3* in NSCLC patients, we analyzed the expression of *ELMO3* at mRNA level by qRT-PCR in NSCLC tissues and adjacent tissues, as well as in NSCLC patients' serum and healthy controls' serum. The expression of *ELMO3* at mRNA level in NSCLC tissues was significantly higher than that in adjacent tissues ($P<0.05$, **Figure 1A**). Similarly, the serum *ELMO3* expression was also markedly up-regulated in patients with NSCLC compared with healthy controls ($P<0.05$, **Figure 1B**). These results indicated that *ELMO3* could be an oncogene in NSCLC.

Correlation between ELMO3 expression and clinicopathological characteristics

To explore whether *ELMO3* expression was relevant to clinicopathological characteristics, we performed chi-square test. As indicated in **Table 1**, *ELMO3* expression was significantly correlated with tumor size ($P=0.020$), TNM stage ($P=0.017$), lymph node metastasis ($P=0.045$) and distant metastasis ($P=0.033$). Nevertheless, no significant correlation was observed among *ELMO3* expression with gender ($P=0.322>0.05$) and age ($P=0.184>0.05$).

Diagnostic value of ELMO3 for NSCLC

ROC curve was established to estimate the diagnostic value of *ELMO3* with the serum




Figure 2. Diagnostic value of *ELMO3* via ROC which had a AUC of 0.917, combining with a sensitivity of 92.8% and a specificity of 84.3%.

ELMO3 expression (**Figure 2**). The AUC value was 0.917 corresponding with a sensitivity of 92.8% and a specificity of 84.3% with a cutoff value was 0.735. This result might demonstrate that *ELMO3* was a potential biomarker for differentiating NSCLC patients.

Association between *ELMO3* expression and overall survival

The relationship between *ELMO3* expression and overall survival time of the patients with NSCLC was evaluated by Kaplan-Meier analysis. As determined by the log-rank test in **Figure 3**, the overall survival time of patients with high *ELMO3* expression was significantly lower than those with low *ELMO3* expression ($P=0.001$). Besides, whether *ELMO3* as well as clinicopathological characteristics could be used as prognostic markers for NSCLC patients were estimated via Cox regression analysis. The outcome indicated that no clinicopathological characteristics but *ELMO3* expression ($P=0.011$, $HR=3.378$, $CI=1.326-8.587$) alone was related to the prognosis of NSCLC. Moreover, it could be an independent prognostic markers in NSCLC (**Table 2**).

Discussion

NSCLC is the leading cause of lung cancer related deaths in world with a characteristic of




Figure 3. Association between *ELMO3* and overall survival time of NSCLC patients according to Kaplan-Meier analysis.

Table 2. Cox regression analysis of *ELMO3* and clinicopathological characteristics

Variables	HR	95% CI	P Value
<i>ELMO3</i> gene	3.378	1.326-8.587	0.011

a long asymptomatic latency and poor prognosis [15 16]. The 5-year survival rate was different along with the change of its stage and the rate could reach to 50% if it was early detected and received treatment [17]. Novel bio-markers with high sensitivity and specificity are therefore urgently needed to the early diagnosis of NSCLC and to promote the development of new treatments [6]. Wang et al. had reported that circulating *MACC1* was expressed higher in NSCLC patients than in benign disease patients or healthy volunteers, represents a potential noninvasive, diagnostic and prognostic marker for NSCLC [18]. Ulivi et al. found peripheral blood miR-328 expression could be as a potential biomarker for the early diagnosis of NSCLC according to relative analysis [19]. Although there are a lot of bio-markers such as mutations in the *KRAS*, epidermal growth factor receptor, *TP53* genes, and changes in the expression levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CK19), cancer antigen-125 (CA125), and neuron-specific enolase (NSE) have been confirmed in NSCLC now [20-22], the clinical value of them were still limited [23, 24].

ELMO3 has the most different protein sequences in *ELMO* family, but modular protein domains are similar with other members [25]. Previous reports have demonstrated that *ELMO* is up-regulated in several cancer tissues, such as human glioma and lung cancer [14, 26, 27]. Molecular alterations between normal lung tissues and tumor tissues, are true drivers of the metastatic process, which are specific to the cohort of patients. *ELMO3* has been a negative impact on the survival of lung cancer patients with distant metastases causing additional morbidities. However, its diagnostic and prognostic role in NSCLC is still unclear.

In the study, we performed qRT-PCR to detect the *ELMO3* expression in NSCLC tissues and adjacent tissues as well as the serum *ELMO3* expression was tested at mRNA level. The result showed that *ELMO3* in NSCLC was significantly higher than that in adjacent tissues and the trend was similar with in serum, implying that *ELMO3* might serve as an oncogene in NSCLC. Besides, *ELMO3* was possible to be related to the occurrence and development of NSCLC through the analysis of the relationship between it and patients' clinicopathological characteristics including tumor size, TNM staging, lymph node metastasis and distance metastasis. The results also verified that *ELMO3* is essential for the progress and metastasis of NSCLC which was consistent with the outcome of previous study [28].

As its abnormal expression, we inferred *ELMO3* could be involved in the diagnosis or prognosis or both of them. Hence, we estimated the diagnostic and prognostic value of *ELMO3* furthermore. For a high AUC value, sensitivity and specificity on the basis of ROC, the diagnostic value of *ELMO3* was considered to be valuable. Meanwhile, the prognostic value was confirmed by Kaplan-Meier and Cox regression analysis. *ELMO3* might be a new potential bio-marker for the early detection and prognosis of NSCLC.

In conclusion, *ELMO3* is over-expressed in NSCLC patients and its expression is influenced by many clinicopathological characteristics including tumor size, TNM stage, lymph node metastasis and distant metastasis. Besides, *ELMO3* is identified to be an independent diagnostic and prognostic indicator in our NSCLC. To our knowledge, this is the first study to investigate the diagnostic and prognostic value of

ELMO3 in NSCLC. There are still several limitations in the study. On the one hand, the sample size of the study is small, and further studies with more patients are required to confirm the results. On the other hand, all of the patients in this study come from one hospital and the results may differ according to the techniques used. Hence, further studies are needed.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Hong Xue, Department of Anesthesiology, Huai'an Hospital Affiliated of Xuzhou Medical College and Huai'an Second People's Hospital, 62 Huaihai Road South, Huai'an 223002, Jiangsu, China. Tel: +86-15161757667; E-mail: xueihong@126.com

References

- [1] Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; 61: 69-90.
- [2] Ramalingam S and Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. *Oncologist* 2008; 13 Suppl 1: 5-13.
- [3] Peters S, Adjei AA, Gridelli C, Reck M, Kerr K and Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012; 23 Suppl 7: vii56-64.
- [4] Li H, Zhang Y, Bai X, Peng Y and He P. TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor. *Tumour Biol* 2014; 35: 5747-52.
- [5] Lee S, Choi EJ, Jin C and Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK-3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. *Gynecol Oncol* 2005; 97: 26-34.
- [6] Alberg AJ, Ford JG and Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007; 132: 29S-55S.
- [7] Xu X and Jin T. A shortcut from GPCR signaling to Rac-mediated actin cytoskeleton through an ELMO/DOCK complex. *Small GTPases* 2012; 3: 183-5.
- [8] Handa Y, Suzuki M, Ohya K, Iwai H, Ishijima N, Koleske AJ, Fukui Y and Sasakawa C. Shigella IpgB1 promotes bacterial entry through the ELMO-Dock180 machinery. *Nat Cell Biol* 2007; 9: 121-8.
- [9] van Ham TJ, Kokel D and Peterson RT. Apoptotic cells are cleared by directional migration

- and elmo1- dependent macrophage engulfment. *Curr Biol* 2012; 22: 830-6.
- [10] Janardhan A, Swigut T, Hill B, Myers MP and Skowronski J. HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis. *PLoS Biol* 2004; 2: E6.
- [11] Ravichandran KS and Lorenz U. Engulfment of apoptotic cells: signals for a good meal. *Nat Rev Immunol* 2007; 7: 964-74.
- [12] Laurin M and Cote JF. Insights into the biological functions of Dock family guanine nucleotide exchange factors. *Genes Dev* 2014; 28: 533-47.
- [13] Coskun M, Boyd M, Olsen J and Troelsen JT. Control of intestinal promoter activity of the cellular migratory regulator gene ELMO3 by CDX2 and SP1. *J Cell Biochem* 2010; 109: 1118-28.
- [14] Soes S, Daugaard IL, Sorensen BS, Carus A, Mattheisen M, Alsner J, Overgaard J, Hager H, Hansen LL and Kristensen LS. Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. *Oncoscience* 2014; 1: 367-74.
- [15] Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. *CA Cancer J Clin* 2010; 60: 277-300.
- [16] Guo S, Yan F, Xu J, Bao Y, Zhu J, Wang X, Wu J, Li Y, Pu W, Liu Y, Jiang Z, Ma Y, Chen X, Xiong M, Jin L and Wang J. Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC). *Clin Epigenetics* 2015; 7: 3.
- [17] Hankey BF, Ries LA and Edwards BK. The surveillance, epidemiology, and end results program: a national resource. *Cancer Epidemiol Biomarkers Prev* 1999; 8: 1117-21.
- [18] Wang Z, Cai M, Weng Y, Zhang F, Meng D, Song J, Zhou H and Xie Z. Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer. *J Cancer Res Clin Oncol* 2014; [Epub ahead of print].
- [19] Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D and Zoli W. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. *Int J Mol Sci* 2013; 14: 10332-42.
- [20] Arya SK and Bhansali S. Lung cancer and its early detection using biomarker-based biosensors. *Chem Rev* 2011; 111: 6783-809.
- [21] Cabrera-Alarcon JL, Carrillo-Vico A, Santotribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A and Guerrero JM. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. *Clin Lab* 2011; 57: 1011-4.
- [22] Gridelli C, Rossi A and Maione P. 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment-first-line therapy. *Eur J Cancer* 2011; 47 Suppl 3: S248-57.
- [23] Cho JY and Sung HJ. Proteomic approaches in lung cancer biomarker development. *Expert Rev Proteomics* 2009; 6: 27-42.
- [24] Wang J, Wang K, Xu J, Huang J and Zhang T. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. *PLoS One* 2013; 8: e78070.
- [25] Goyette MA and Cote JF. NSCLC metastasis: going with ELMO3. *Oncotarget* 2014; 5: 5850-1.
- [26] Jarzynka MJ, Hu B, Hui KM, Bar-Joseph I, Gu W, Hirose T, Haney LB, Ravichandran KS, Nishikawa R and Cheng SY. ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. *Cancer Res* 2007; 67: 7203-11.
- [27] Rapa E, Hill SK, Morten KJ, Potter M and Mitchell C. The over-expression of cell migratory genes in alveolar rhabdomyosarcoma could contribute to metastatic spread. *Clin Exp Metastasis* 2012; 29: 419-29.
- [28] Zhou Z, Caron E, Hartwig E, Hall A and Horvitz HR. The C. elegans PH domain protein CED-12 regulates cytoskeletal reorganization via a Rho/Rac GTPase signaling pathway. *Dev Cell* 2001; 1: 477-89.